Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hannah Zaryouh"'
Autor:
Hasan Baysal, Vasiliki Siozopoulou, Hannah Zaryouh, Christophe Hermans, Ho Wa Lau, Hilde Lambrechts, Erik Fransen, Ines De Pauw, Julie Jacobs, Marc Peeters, Patrick Pauwels, Jan Baptist Vermorken, Evelien Smits, Filip Lardon, Jorrit De Waele, An Wouters
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that retain their poor prognosis despite recent advances in their standard of care. As the involvement of the immune system against HNSCC development is well-recognized,
Externí odkaz:
https://doaj.org/article/c58e7c1d2db342af9441c51ad1dbe781
Autor:
Hannah Zaryouh, Jinthe Van Loenhout, Marc Peeters, Jan Baptist Vermorken, Filip Lardon, An Wouters
Publikováno v:
Cancers, Vol 14, Iss 24, p 6128 (2022)
Resistance to EGFR-targeted therapy is a major obstacle on the road to effective treatment options for head and neck cancers. During the search for underlying mechanisms and regulators of this resistance, there were several indications that EGFR-targ
Externí odkaz:
https://doaj.org/article/03c98c50f9bc4ce5831bb20c551e7cb0
Autor:
Hasan Baysal, Ines De Pauw, Hannah Zaryouh, Marc Peeters, Jan Baptist Vermorken, Filip Lardon, Jorrit De Waele, An Wouters
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Cetuximab has an established role in the treatment of patients with recurrent/metastatic colorectal cancer and head and neck squamous cell cancer (HNSCC). However, the long-term effectiveness of cetuximab has been limited by the development of acquir
Externí odkaz:
https://doaj.org/article/3d3269b3d0d44fd38559cddf279054ad
Autor:
Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Patrick Pauwels, Marc Peeters, Jan Baptist Vermorken, Filip Lardon, An Wouters
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as cetuximab, poses a challenging problem. This study aims to characterize acquired cetu
Externí odkaz:
https://doaj.org/article/9c0cba2fff934b7ebc585ed25872b544
Autor:
Hannah Zaryouh, Ines De Pauw, Marc Peeters, Jan B. Vermorken, Hasan Baysal, Filip Lardon, An Wouters
Publikováno v:
Medicinal research reviews
Resistance to therapies targeting the epidermal growth factor receptor (EGFR), such as cetuximab, remains a major roadblock in the search for effective therapeutic strategies in head and neck squamous cell carcinoma (HNSCC). Due to its close interact
Autor:
Jorrit De Waele, Marc Peeters, Evelien Smits, Filip Lardon, Jan B Vermorken, Julie Jacobs, Hasan Baysal, An Wouters, Patrick Pauwels, Hannah Zaryouh, Ines De Pauw
Publikováno v:
British Journal of Cancer
The British journal of cancer
The British journal of cancer
Background The epidermal growth factor receptor (EGFR) is overexpressed by 80–90% of squamous cell carcinoma of head and neck (HNSCC). In addition to inhibiting EGFR signal transduction, cetuximab, a monoclonal antibody targeting EGFR can also bind
Autor:
Valentin Van den bossche, Hannah Zaryouh, Marianela Vara-Messler, Julie Vignau, Jean-Pascal Machiels, An Wouters, Sandra Schmitz, Cyril Corbet
Publikováno v:
Drug resistance updates
Squamous cell carcinoma of the head and neck (SCCHN) is among the most prevalent cancer types worldwide. Despite multimodal therapeutic approaches that include surgical resection, radiation therapy or concurrent chemoradiation, targeted therapy and i
Autor:
Marc Peeters, Patrick Pauwels, Jan B. Vermorken, Hasan Baysal, Hannah Zaryouh, Ines De Pauw, Filip Lardon, An Wouters
Publikováno v:
Cancer Research. 81:1095-1095
Resistance to therapies targeting the epidermal growth factor receptor (EGFR), such as cetuximab, remains a major roadblock in the search for effective therapeutic strategies in head and neck squamous cell carcinoma (HNSCC). Increasing evidence sugge
Autor:
Marc Peeters, Jan B. Vermorken, Hasan Baysal, Filip Lardon, Evelien Smits, An Wouters, Julie Jacobs, Hannah Zaryouh, Ines De Pauw
Publikováno v:
Cancer Research. 80:3371-3371
The epidermal growth factor receptor (EGFR)-targeted therapies and immunotherapies are now at the forefront for treatment of head and neck squamous cell carcinoma (HNSCC). However, resistance to cetuximab, an anti-EGFR monoclonal antibody (mAb), is a